PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30765674-5	2019	Neoadjuvant chemotherapy was chosen, and then combined treatment with epirubicin(EPI)and cyclophosphamide(CPA) was started.	Cyclophosphamide	89-105	carboxypeptidase A1	Homo sapiens	106-109	
21918347-1	2011	We experienced a case of locally advanced breast cancer achieving a significant improvement by using a combination of docetaxel(DOC), cyclophosphamide(CPA)and trastuzumab as a primary systemic therapy.The patient was a 54-year-old woman suffering from a right breast mass, who was referred to our hospital and diagnosed with HER2-positive breast cancer with subclavicular lymph nodes metastases.The combination therapy of DOC(75 mg/m / 2), CPA(600 mg/m2)and trastuzumab(loading dose 8 mg/kg, then 6 mg/kg)for 6 courses at q3 week intervals, was started as the primary systemic therapy.	Cyclophosphamide	134-150	carboxypeptidase A1	Homo sapiens	151-154	
24917007-4	2014	Against this background, we measured the time required to prepare cyclophosphamide(CPA)and estimated the cost incurred.	Cyclophosphamide	66-82	carboxypeptidase A1	Homo sapiens	83-86	
24917012-6	2014	The patient began receiving different regimens of chemotherapy: 5-fluorouracil (5-FU), epirubicin (EPI), and cyclophosphamide(CPA), (FEC); PTX; docetaxel (DTX); and gemcitabine (GEM) plus PTX.	Cyclophosphamide	109-125	carboxypeptidase A1	Homo sapiens	126-129	
24047774-2	2013	A phase I study of sequential S-1 and cyclophosphamide(CPA)therapy was conducted to determine the dose-limiting toxicities(DLTs)and recommended doses(RDs)in patients with metastatic or recurrent breast cancer(MBC).	Cyclophosphamide	38-54	carboxypeptidase A1	Homo sapiens	55-58